Loading…
GNLX
GENELUX Corp
NASDAQ· Healthcare· Biotechnology· CUSIP 36870H103
$2.66-7.64%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $120.35M
- P/E
- —
- Forward P/E
- —
- P/B
- 7.5x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.86
- ROE
- -177.93%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.59
- 52-week high
- $8.54
- 52-week low
- $2.29
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -56.7% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $4.36 | $2.36 | $14.01 | |
| P/S | 11131.8x | 24419.2x | 11131.8x | 2214.0x |
| P/B | 16.9x | 16.9x | 3.4x | 19.3x |
| EPS | -$0.86 | -$0.95 | -$1.16 | |
| Profit margin | -373362.50% | -401812.50% | -373362.50% | -16645.29% |
| ROE |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| QUCYQuantum Cyber N.V. | $1.42 | — | 1.7x | — | -212.53% | $119.38M |
| NTHINeonc Technologies Holdings Inc | $4.69 | — | — | — | — | $121.64M |
| JYNTJOINT Corp | $8.38 | 59.9x | 7.2x | — | 10.62% | $118.52M |
| ENGNenGene Therapeutics Inc. | $1.83 |
About the company
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
- 25
- Westlake Village, United States
Company description provided by Yahoo Finance.